On Tuesday, Taysha Gene Therapies Inc (NASDAQ: TSHA) was 3.95% up from the session before settling in for the closing price of $2.53. A 52-week range for TSHA has been $1.05 – $3.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -63.99% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 13.55%. With a float of $213.39 million, this company’s outstanding shares have now reached $261.53 million.
In an organization with 73 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 72.63%, operating margin of -1225.78%, and the pretax margin is -1201.08%.
Taysha Gene Therapies Inc (TSHA) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Taysha Gene Therapies Inc stocks. The insider ownership of Taysha Gene Therapies Inc is 18.41%, while institutional ownership is 66.25%. The most recent insider transaction that took place on May 30 ’25, was worth 2,062,500. In this transaction 10% Owner of this company bought 750,000 shares at a rate of $2.75, taking the stock ownership to the 2,841,704 shares.
Taysha Gene Therapies Inc (TSHA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 13.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.39% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
You can see what Taysha Gene Therapies Inc (TSHA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 95.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.37 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Let’s dig in a bit further. During the last 5-days, its volume was 3.65 million. That was better than the volume of 2.93 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 55.85%.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 72.15%, which indicates a significant decrease from 75.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.15 in the past 14 days, which was lower than the 0.18 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.57, while its 200-day Moving Average is $2.02. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $2.75. Second resistance stands at $2.88. The third major resistance level sits at $3.08. If the price goes on to break the first support level at $2.42, it is likely to go to the next support level at $2.22. Assuming the price breaks the second support level, the third support level stands at $2.09.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are 214,662K outstanding shares of the company, which has a market capitalization of 687.82 million. As of now, sales total 8,330 K while income totals -89,300 K. Its latest quarter income was 2,300 K while its last quarter net income were -21,530 K.
